Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD)1 presented at the 63rd American Society of Hematology (ASH) Annual Meeting. “Precision's cl

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, Decemb

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021. Presentation Details: Abstract Number and Title: Abstract #03. Targeting Hepatitis B cccD

Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 98% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 98% Upside in Precision BioSciences (DTIL): Can the Stock Really Move This High?

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #earnings--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “Precision is dedicated to delivering on the vast potential of ARCUS gene editing for best-in-class cell and gene therapeutics. In addition to significant research and

Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

Precision BioSciences Earnings Preview

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #SITC21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that the abstract titled, “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10 –

Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc., and Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company's Board of

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D.

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that investigators involved with the Phase 1/2a study of PBCAR0191 in Relapsed/Refractory (R/R) non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL), will present new data during two oral presentations at the 63rd Annual Meeting of the Amer

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2021 and provide a business update on November 10, 2021. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in a fireside chat at the Stifel 2021 Virtual

Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Precision BioSciences (DTIL) to Report a Decline in Earnings: What to Look Out for

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit, being held October 27-28, 2021. Details for the fireside chat are below: Jefferies Virtual Gene Therapy/Gene Editing Summit Da

Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021

DTIL has developed its own proprietary genome editing technology, ARCUS, with the potential to deliver safer therapies compared to other more common genome editing technologies.

Precision BioSciences: Uniquely Positioned

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences. The Compensation Committee of the Company's Board of Directors has granted to Mr. Amoroso, effective with his commencement of employment (the “

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #CEO--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the Company's President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021. Mr. Amoroso will succeed Matt Kane, Co-Founder, President and Chief Exe

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021. The pre-recorded presentation will be made available for on-demand viewing starting Monday, September 13, 2021 at 7:00 a.m. ET on the Com

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's PCSK9-directed ARCUS nuclease to develop additional gene-editing therapies for genetic diseases, initially targeting liver diseases.

Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today provided strategic business updates on its in vivo gene editing pipeline during the Company's first gene editing R&D event. “Gene editing promises to fundamentally reshape the treatment landscape across numerous therapeutic categories. Today's in vivo gene editing R&a

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

DURHAM, N.C. & PHILADELPHIA--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced a license and collaboration agreement under which iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 stud

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.

Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate

The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 4% during intraday trading. This is why it happened.

DTIL Stock: Over 4% Increase Explanation

Tiziana Life Sciences Ltd

Shares in Tiziana Life Sciences PLC raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The tie-up takes it into the exciting arena of CAR-T therapy with the pair looking to use Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of cancer treatments.

Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells.

Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications

Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies.

Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies. CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene (now owned by Bristol Myers Squibb) and Gilead Sciences (NASDAQ:GILD) underscore the interest in this emerging area of biotechnology.

News for Precision Biosciences Stock (DTIL)